Pfizer covid-19 vaccine has 100% long-term efficacy in adolescents: trial data
- Select a language for the TTS:
- UK English Female
- UK English Male
- US English Female
- US English Male
- Australian Female
- Australian Male
- Language selected: (auto detect) - EN
Play all audios:
A safety follow up of participants of the phase 3 clinical trials was conducted by Pfizer 6 months after they were given the second dose. According to the company, "the adverse event
profile was generally consistent with other clinical safety data for the vaccine, with no serious safety concerns observed." Case studies of 2,228 trial participants of the clinical
trial were analysed over the course of the 6 months after primary vaccination (2 doses), and the results were found to be consistent with the earlier released trial results. The efficacy was
also found to be consistent across sexes, ethnicities, races, and those with comorbidity status. The company has said that it also plans to release this data for peer review soon.